Omeros (NASDAQ:OMER) Shares Gap Down – What’s Next?

Omeros Co. (NASDAQ:OMER) gapped down before the market opened on Wednesday . The stock had previously closed at $12.15, but opened at $11.85. Omeros shares last traded at $11.85, with a volume of 1,188 shares trading hands.

Wall Street Analyst Weigh In

Several brokerages recently commented on OMER. StockNews.com raised Omeros from a “sell” rating to a “hold” rating in a research report on Wednesday, November 20th. Cantor Fitzgerald reissued a “neutral” rating on shares of Omeros in a research report on Thursday, November 14th. Needham & Company LLC reaffirmed a “hold” rating on shares of Omeros in a research report on Thursday, November 14th. Rodman & Renshaw assumed coverage on Omeros in a research report on Thursday, November 14th. They issued a “buy” rating and a $9.00 price objective for the company. Finally, RODMAN&RENSHAW raised Omeros to a “strong-buy” rating in a research report on Thursday, November 14th. Three investment analysts have rated the stock with a hold rating, one has given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $9.00.

Omeros Stock Performance

The stock has a 50 day moving average price of $4.83 and a two-hundred day moving average price of $4.36.

Hedge Funds Weigh In On Omeros

Hedge funds have recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets increased its stake in Omeros by 130.6% during the 3rd quarter. BNP Paribas Financial Markets now owns 12,388 shares of the biopharmaceutical company’s stock worth $49,000 after acquiring an additional 7,016 shares during the period. MML Investors Services LLC increased its stake in Omeros by 19.2% during the 3rd quarter. MML Investors Services LLC now owns 18,600 shares of the biopharmaceutical company’s stock worth $74,000 after acquiring an additional 3,000 shares during the period. SPC Financial Inc. bought a new position in Omeros during the 3rd quarter worth $77,000. SG Americas Securities LLC bought a new position in Omeros during the 3rd quarter worth $80,000. Finally, Comerica Bank increased its stake in Omeros by 20.0% during the 1st quarter. Comerica Bank now owns 30,000 shares of the biopharmaceutical company’s stock worth $104,000 after acquiring an additional 5,000 shares during the period. Institutional investors own 48.79% of the company’s stock.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.